Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy

OncoImmunology

Volumn 3, Issue 2, 2014, Pages

  Aranda, Fernando ^a,b,c   Vacchelli, Erika ^a,b,c,d   Eggermont, Alexander ^a   Galon, Jerome ^c,e,f,g   Fridman, Wolf Hervé ^c,f,g   Zitvogel, Laurence ^a,h   Kroemer, Guido ^b,c,e,i,j   Galluzzi, Lorenzo ^a,c,e  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b Institut Gustave Roussy   (France)

^c CENTRE DE RECHERCHE DES CORDELIERS   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f SORBONNE UNIVERSITÉ   (France)

^g INSER M U872   (France)

^h University Paris XI   (France)

ⁱ HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^j Metabolomics Platform   (France)

more..

Author keywords

CD137; Checkpoint blockade; Immunogenic chemotherapy; Immunosuppression; IPH2101; Lirilumab; PD L1

Indexed keywords

9 B 12; 9B12; AMP 224; BMS 936559; CD134 ANTIGEN; CP 870 893; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACETUZUMAB; FRESOLIMUMAB; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; IMP 321; IPH 2101; IPILIMUMAB; LIRILUMAB; LUCATUMUMAB; MEDI 4736; MEDI 6469; MONOCLONAL ANTIBODY; MPDL 3280 A; MSB 0010718 C; NIVOLUMAB; PEMBROLIZUMAB; PF 05082566; PIDILIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; TICILIMUMAB; TRX 518; UNCLASSIFIED DRUG; UNINDEXED DRUG; URELUMAB; VARLILUMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELLULAR IMMUNITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; COLORECTAL CARCINOMA; CYTOTOXIC T LYMPHOCYTE; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; GLIOMA; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; IMMUNOSTIMULATION; LARGE CELL LYMPHOMA; LEUKEMIA; LIVER CELL CARCINOMA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MERKEL CELL TUMOR; MESOTHELIOMA; METASTATIC MELANOMA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NAUSEA; NONHODGKIN LYMPHOMA; PANCREAS CANCER; PANCREAS CARCINOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CARCINOMA; PRURITUS; RASH; REVIEW; SOLID TUMOR; UTERINE CERVIX CARCINOMA; UVEA MELANOMA;

EID: 84899112560     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.27297     Document Type: Review

References (124)

1. Alkan SS. Monoclonal antibodies: the story of a discovery that revolutionized science and medicine. Nat Rev Immunol 2004; 4:153-6; PMID:15040588; http://dx.doi.org/10.1038/nri1265.
2. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010; 10:317-27; PMID:20414205; http://dx.doi.org/10.1038/nri2744.
3. Melero I, Grimaldi AM, Perez-Gracia JL, Ascierto PA. Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res 2013; 19:997-1008; PMID:23460531; http://dx.doi.org/10.1158/1078-0432.CCR-12-2214.
4. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007; 7:95-106; PMID:17251916; http://dx.doi.org/10.1038/nrc2051.
5. Gray JC, Johnson PW, Glennie MJ. Therapeutic potential of immunostimulatory monoclonal antibodies. Clin Sci (Lond) 2006; 111:93-106; PMID:16831129; http://dx.doi.org/10.1042/CS20060024.
6. Galluzzi L, Vacchelli E, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zucman-Rossi J, Zitvogel L, Kroemer G. Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology 2012; 1:28-37; PMID:22720209; http://dx.doi. org/10.4161/onci.1.1.17938.
7. Vacchelli E, Eggermont A, Galon J, Sautès-Fridman C, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology 2013; 2:e22789; PMID:23482847; http://dx.doi.org/10.4161/onci.22789.
8. Vacchelli E, Aranda F, Eggermont A, Galon J, Sautes-Fridman C, Zitvogel L, et al. Trial Watch: Tumortargeting monoclonal antibodies in cancer therapy. OncoImmunology 2014; Forthcoming.
9. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3:391-400; PMID:15136787; http://dx.doi.org/10.1038/nrd1381.
10. Michielsen AJ, Ryan EJ, O'Sullivan JN. Dendritic cell inhibition correlates with survival of colorectal cancer patients on bevacizumab treatment. Oncoimmunology 2012; 1:1445-7; PMID:23243624; http://dx.doi.org/10.4161/onci.21318.
11. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235-42; PMID:11807147; http://dx.doi. org/10.1056/NEJMoa011795.
12. McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16:2825-33; PMID:9704735.
13. Sorbye SW, Kilvaer T, Valkov A, Donnem T, Smeland E, Al-Shibli K, Bremnes RM, Busund LT. High expression of CD20+ lymphocytes in soft tissue sarcomas is a positive prognostic indicator. Oncoimmunology 2012; 1:75-7; PMID:22720216; http://dx.doi.org/10.4161/onci.1.1.17825.
14. Nimmerjahn F, Ravetch JV. Fcgamma receptors: old friends and new family members. Immunity 2006; 24:19-28; PMID:16413920; http://dx.doi. org/10.1016/j.immuni.2005.11.010.
15. Hubert P, Amigorena S. Antibody-dependent cell cytotoxicity in monoclonal antibody-mediated tumor immunotherapy. Oncoimmunology 2012; 1:103-5; PMID:22720225; http://dx.doi.org/10.4161/onci.1.1.17963.
16. Houot R, Kohrt H, Levy R. Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody. Oncoimmunology 2012; 1:957-8; PMID:23162770; http://dx.doi. org/10.4161/onci.19974.
17. Kute T, Stehle JR Jr., Ornelles D, Walker N, Delbono O, Vaughn JP. Understanding key assay parameters that affect measurements of trastuzumab-mediated ADCC against Her2 positive breast cancer cells. Oncoimmunology 2012; 1:810-21; PMID:23162748; http://dx.doi.org/10.4161/onci.20447.
18. Winiarska M, Glodkowska-Mrowka E, Bil J, Golab J. Molecular mechanisms of the antitumor effects of anti-CD20 antibodies. Front Biosci (Landmark Ed) 2011; 16:277-306; PMID:21196171; http://dx.doi. org/10.2741/3688.
19. Dunkelberger JR, Song WC. Complement and its role in innate and adaptive immune responses. Cell Res 2010; 20:34-50; PMID:20010915; http://dx.doi. org/10.1038/cr.2009.139.
20. Zipfel PF, Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol 2009; 9:729-40; PMID:19730437.
21. Weiner LM, Belldegrun AS, Crawford J, Tolcher AW, Lockbaum P, Arends RH, Navale L, Amado RG, Schwab G, Figlin RA. Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clin Cancer Res 2008; 14:502-8; PMID:18223225; http://dx.doi. org/10.1158/1078-0432.CCR-07-1509.
22. Ming Lim C, Stephenson R, Salazar AM, Ferris RL. TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR(+) head and neck cancer cells. Oncoimmunology 2013; 2:e24677; PMID:23894722; http://dx.doi.org/10.4161/onci.24677.
23. Kawaguchi Y, Kono K, Mimura K, Sugai H, Akaike H, Fujii H. Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer 2007; 120:781-7; PMID:17096332; http://dx.doi. org/10.1002/ijc.22370.
24. Srivastava RM, Lee SC, Andrade Filho PA, Lord CA, Jie HB, Davidson HC, López-Albaitero A, Gibson SP, Gooding WE, Ferrone S, et al. Cetuximabactivated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res 2013; 19:1858-72; PMID:23444227; http://dx.doi. org/10.1158/1078-0432.CCR-12-2426.
25. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret al.y: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11:215-33; PMID:22301798; http://dx.doi.org/10.1038/nrd3626.
26. Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013; 39:74-88; PMID:23890065; http://dx.doi.org/10.1016/j.immuni.2013.06.014.
27. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:2453-63; PMID:12011122; http://dx.doi. org/10.1200/JCO.2002.11.076.
28. Kaminski MS, Estes J, Zasadny KR, Francis IR, Ross CW, Tuck M, Regan D, Fisher S, Gutierrez J, Kroll S, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000; 96:1259-66; PMID:10942366.
29. Walker LS, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol 2011; 11:852-63; PMID:22116087; http://dx.doi.org/10.1038/nri3108.
30. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004; 4:336-47; PMID:15122199; http://dx.doi.org/10.1038/nri1349.
31. Waitz R, Fassò M, Allison JP. CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection. Oncoimmunology 2012; 1:544-6; PMID:22754781; http://dx.doi.org/10.4161/onci.19442.
32. Munir S, Andersen GH, Svane IM, Andersen MH. The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4(+) T cells. Oncoimmunology 2013; 2:e23991; PMID:23734334; http://dx.doi.org/10.4161/onci.23991.
33. Zitvogel L, Kroemer G. Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology 2012; 1:1223-5; PMID:23243584; http://dx.doi. org/10.4161/onci.21335.
34. Fife BT, Pauken KE, Eagar TN, Obu T, Wu J, Tang Q, Azuma M, Krummel MF, Bluestone JA. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol 2009; 10:1185-92; PMID:19783989; http://dx.doi.org/10.1038/ni.1790.
35. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 2007; 8:239-45; PMID:17304234; http://dx.doi.org/10.1038/ni1443.
36. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001; 2:261-8; PMID:11224527; http://dx.doi. org/10.1038/85330.
37. Raulet DH, Guerra N. Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat Rev Immunol 2009; 9:568-80; PMID:19629084; http://dx.doi.org/10.1038/nri2604.
38. Smyth MJ, Hayakawa Y, Takeda K, Yagita H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2002; 2:850-61; PMID:12415255; http://dx.doi.org/10.1038/nrc928.
39. Joncker NT, Raulet DH. Regulation of NK cell responsiveness to achieve self-tolerance and maximal responses to diseased target cells. Immunol Rev 2008; 224:85-97; PMID:18759922; http://dx.doi. org/10.1111/j.1600-065X.2008.00658.x.
40. Long EO. Negative signaling by inhibitory receptors: the NK cell paradigm. Immunol Rev 2008; 224:70-84; PMID:18759921; http://dx.doi. org/10.1111/j.1600-065X.2008.00660.x.
41. Withers DR, Gaspal FM, Bekiaris V, McConnell FM, Kim M, Anderson G, Lane PJ. OX40 and CD30 signals in CD4(+) T-cell effector and memory function: a distinct role for lymphoid tissue inducer cells in maintaining CD4(+) T-cell memory but not effector function. Immunol Rev 2011; 244:134-48; PMID:22017436; http://dx.doi. org/10.1111/j.1600-065X.2011.01057.x.
42. Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol 2009; 9:271-85; PMID:19319144; http://dx.doi. org/10.1038/nri2526.
43. Sugamura K, Ishii N, Weinberg AD. Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol 2004; 4:420-31; PMID:15173831; http://dx.doi.org/10.1038/nri1371.
44. Hombach AA, Heiders J, Foppe M, Chmielewski M, Abken H. OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells. Oncoimmunology 2012; 1:458-66; PMID:22754764; http://dx.doi. org/10.4161/onci.19855.
45. Shevach EM, Stephens GL. The GITR-GITRL interaction: co-stimulation or contrasuppression of regulatory activity? Nat Rev Immunol 2006; 6:613-8; PMID:16868552; http://dx.doi.org/10.1038/nri1867.
46. Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002; 3:135-42; PMID:11812990; http://dx.doi.org/10.1038/ni759.
47. Chen W, Frank ME, Jin W, Wahl SM. TGF-beta released by apoptotic T cells contributes to an immunosuppressive milieu. Immunity 2001; 14:715-25; PMID:11420042; http://dx.doi.org/10.1016/S1074-7613(01)00147-9.
48. Schnurr M, Duewell P. Breaking tumor-induced immunosuppression with 5¢-triphosphate siRNA silencing TGFβ and activating RIG-I. Oncoimmunology 2013; 2:e24170; PMID:23762798; http://dx.doi. org/10.4161/onci.24170.
49. Gorelik L, Flavell RA. Transforming growth factorbeta in T-cell biology. Nat Rev Immunol 2002; 2:46-53; PMID:11905837; http://dx.doi.org/10.1038/nri704.
50. Pickup M, Novitskiy S, Moses HL. The roles of TGFβ in the tumour microenvironment. Nat Rev Cancer 2013; 13:788-99; PMID:24132110; http://dx.doi.org/10.1038/nrc3603.
51. Ikushima H, Miyazono K. TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer 2010; 10:415-24; PMID:20495575; http://dx.doi. org/10.1038/nrc2853.
52. LoBuglio AF, Saleh MN, Lee J, Khazaeli MB, Carrano R, Holden H, Wheeler RH. Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. I. Clinical aspects. J Natl Cancer Inst 1988; 80:932-6; PMID:3398068; http://dx.doi. org/10.1093/jnci/80.12.932.
53. Lobuglio AF, Saleh M, Peterson L, Wheeler R, Carrano R, Huster W, Khazaeli MB. Phase I clinical trial of CO17-1A monoclonal antibody. Hybridoma 1986; 5(Suppl 1):S117-23; PMID:3488950.
54. Sears HF, Herlyn D, Steplewski Z, Koprowski H. Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma. Cancer Res 1985; 45:5910-3; PMID:4053061.
55. Sears HF, Atkinson B, Mattis J, Ernst C, Herlyn D, Steplewski Z, Häyry P, Koprowski H. Phase-I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours. Lancet 1982; 1:762-5; PMID:6121224; http://dx.doi.org/10.1016/S0140-6736(82)91811-6.
56. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12:991-1045; PMID:8011301; http://dx.doi.org/10.1146/annurev. iy.12.040194.005015.
57. Matzinger P. The danger model: a renewed sense of self. Science 2002; 296:301-5; PMID:11951032; http://dx.doi.org/10.1126/science.1071059.
58. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466.
59. Robert C, Thomas L, Bondarenko I, O'Day S, Jeffrey Weber, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-26; PMID:21639810; http://dx.doi. org/10.1056/NEJMoa1104621.
60. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie T Jr., et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11:155-64; PMID:20004617; http://dx.doi.org/10.1016/S1470-2045(09)70334-1.
61. Sosman J, Sznol M, McDermott D, Carvajal RD, Lawrence DP, Topalian SL, et al. Clinical activity and safety of anti-programmed death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in patients (pts) with advanced melanoma (mel). Ann Oncol 2012; 23: ix367-75.
62. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28:3167-75; PMID:20516446; http://dx.doi. org/10.1200/JCO.2009.26.7609.
63. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-65; PMID:22658128; http://dx.doi.org/10.1056/NEJMoa1200694.
64. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690.
65. Patnaik A, Kang SP, Tolcher AW, Rasco DW, Papadopoulos KP, Beeram M, et al. Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. J Clin Oncol 2012; 30:abstr 2512.
66. Tykodi SS, Brahmer JR, Hwu WJ, Chow LQ, Hwu P, Odunsi K, et al. PD-1/PD-L1 pathway as a target for cancer immunotherapy: safety and clinical activity of BMS-936559, an anti-PD-L1 antibody, in patients with solid tumors. J Clin Oncol 2012; 30:abstr 2510.
67. Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, Hutnick NA, Sullivan P, Mahany JJ, Gallagher M, Kramer A, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 2007; 25:876-83; PMID:17327609; http://dx.doi.org/10.1200/JCO.2006.08.3311.
68. Hussein M, Berenson JR, Niesvizky R, Munshi N, Matous J, Sobecks R, Harrop K, Drachman JG, Whiting N. A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica 2010; 95:845-8; PMID:20133895; http://dx.doi.org/10.3324/haematol.2009.008003.
69. Furman RR, Forero-Torres A, Shustov A, Drachman JG. A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leuk Lymphoma 2010; 51:228-35; PMID:20038235; http://dx.doi.org/10.3109/10428190903440946.
70. Ascierto PA, Simeone E, Sznol M, Fu YX, Melero I. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol 2010; 37:508-16; PMID:21074066; http://dx.doi.org/10.1053/j. seminoncol.2010.09.008.
71. Molckovsky A, Siu LL. First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting. J Hematol Oncol 2008; 1:20; PMID:18959794; http://dx.doi.org/10.1186/1756-8722-1-20.
72. Aranda F, Vacchelli E, Eggermont A, Galon J, Sautes-Fridman C, Tartour E, et al. Trial Watch: Peptide vaccines in cancer therapy. OncoImmunology 2013; 2:e26621.
73. Vacchelli E, Martins I, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology 2012; 1:1557-76; PMID:23264902; http://dx.doi.org/10.4161/onci.22428.
74. Vacchelli E, Galluzzi L, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Kroemer G. Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2012; 1:179-88; PMID:22720239; http://dx.doi.org/10.4161/onci.1.2.19026.
75. Vacchelli E, Senovilla L, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2013; 2:e23510; PMID:23687621; http://dx.doi.org/10.4161/onci.23510.
76. Sherrill B, Wang J, Kotapati S, Chin K. Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma. Br J Cancer 2013; 109:8-13; PMID:23787916; http://dx.doi.org/10.1038/bjc.2013.298.
77. Santegoets SJ, Stam AG, Lougheed SM, Gall H, Scholten PE, Reijm M, Jooss K, Sacks N, Hege K, Lowy I, et al. T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment. Cancer Immunol Immunother 2013; 62:245-56; PMID:22878899; http://dx.doi. org/10.1007/s00262-012-1330-5.
78. Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013; 368:1365-6; PMID:23550685; http://dx.doi.org/10.1056/NEJMc1302338.
79. Reck M, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Lu H, Cuillerot JM, Lynch TJ. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 2013; 24:75-83; PMID:22858559; http://dx.doi.org/10.1093/annonc/mds213.
80. Le DT, Lutz E, Uram JN, Sugar EA, Onners B, Solt S, Zheng L, Diaz LA Jr., Donehower RC, Jaffee EM, et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother 2013; 36:382-9; PMID:23924790; http://dx.doi.org/10.1097/CJI.0b013e31829fb7a2.
81. Kwek SS, Dao V, Roy R, Hou Y, Alajajian D, Simko JP, Small EJ, Fong L. Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients. J Immunol 2012; 189:3759-66; PMID:22956585; http://dx.doi.org/10.4049/jimmunol.1201529.
82. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369:122-33; PMID:23724867; http://dx.doi. org/10.1056/NEJMoa1302369.
83. Ribas A, Chesney JA, Gordon MS, Abernethy AP, Logan TF, Lawson DH, Chmielowksi B, Glaspy JA, Lewis K, Huang B, et al. Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion. J Transl Med 2012; 10:236; PMID:23171508; http://dx.doi.org/10.1186/1479-5876-10-236.
84. Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 2013; 31:616-22; PMID:23295794; http://dx.doi.org/10.1200/JCO.2012.44.6112.
85. Millward M, Underhill C, Lobb S, McBurnie J, Meech SJ, Gomez-Navarro J, Marshall MA, Huang B, Mather CB. Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours. Br J Cancer 2013; 108:1998-2004; PMID:23652314; http://dx.doi.org/10.1038/bjc.2013.227.
86. Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA, Xu H, Yao S, Pons A, Chen L, et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res 2013; 19:462-8; PMID:23169436; http://dx.doi.org/10.1158/1078-0432.CCR-12-2625.
87. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369:134-44; PMID:23724846; http://dx.doi. org/10.1056/NEJMoa1305133.
88. Vey N, Bourhis JH, Boissel N, Bordessoule D, Prebet T, Charbonnier A, Etienne A, Andre P, Romagne F, Benson D, et al. A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood 2012; 120:4317-23; PMID:23002117; http://dx.doi.org/10.1182/blood-2012-06-437558.
89. Benson DM Jr., Hofmeister CC, Padmanabhan S, Suvannasankha A, Jagannath S, Abonour R, Bakan C, Andre P, Efebera Y, Tiollier J, et al. A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood 2012; 120:4324-33; PMID:23033266; http://dx.doi. org/10.1182/blood-2012-06-438028.
90. Vonderheide RH, Burg JM, Mick R, Trosko JA, Li D, Shaik MN, Tolcher AW, Hamid O. Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. Oncoimmunology 2013; 2:e23033; PMID:23483678; http://dx.doi. org/10.4161/onci.23033.
91. Forero-Torres A, Bartlett N, Beaven A, Myint H, Nasta S, Northfelt DW, Whiting NC, Drachman JG, Lobuglio AF, Moskowitz CH. Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma. Leuk Lymphoma 2013; 54:277-83; PMID:22775314; http://dx.doi.org/10.3109/10 428194.2012.710328.
92. Beatty GL, Torigian DA, Chiorean EG, Saboury B, Brothers A, Alavi A, Troxel AB, Sun W, Teitelbaum UR, Vonderheide RH, et al. A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer Res 2013; 19:6286-95; PMID:23983255; http://dx.doi.org/10.1158/1078-0432.CCR-13-1320.
93. Byrd JC, Kipps TJ, Flinn IW, Cooper M, Odenike O, Bendiske J, Rediske J, Bilic S, Dey J, Baeck J, et al. Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. Leuk Lymphoma 2012; 53:2136-42; PMID:22475052; http://dx.doi. org/10.3109/10428194.2012.681655.
94. Curti BD, Kovacsovics-Bankowski M, Morris N, Walker E, Chisholm L, Floyd K, Walker J, Gonzalez I, Meeuwsen T, Fox BA, et al. OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients. Cancer Res 2013; 73:7189-98; PMID:24177180; http://dx.doi.org/10.1158/0008-5472.CAN-12-4174.
95. Wang-Gillam A, Plambeck-Suess S, Goedegebuure P, Simon PO, Mitchem JB, Hornick JR, Sorscher S, Picus J, Suresh R, Lockhart AC, et al. A phase I study of IMP321 and gemcitabine as the frontline therapy in patients with advanced pancreatic adenocarcinoma. Invest New Drugs 2013; 31:707-13; PMID:22864469; http://dx.doi.org/10.1007/s10637-012-9866-y.
96. Hoffmann J, Vitale I, Buchmann B, Galluzzi L, Schwede W, Senovilla L, Skuballa W, Vivet S, Lichtner RB, Vicencio JM, et al. Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. Cancer Res 2008; 68:5301-8; PMID:18593931; http://dx.doi. org/10.1158/0008-5472.CAN-08-0237.
97. Senovilla L, Vitale I, Martins I, Tailler M, Pailleret C, Michaud M, Galluzzi L, Adjemian S, Kepp O, Niso-Santano M, et al. An immunosurveillance mechanism controls cancer cell ploidy. Science 2012; 337:1678-84; PMID:23019653; http://dx.doi. org/10.1126/science.1224922.
98. Michels J, Vitale I, Galluzzi L, Adam J, Olaussen KA, Kepp O, Senovilla L, Talhaoui I, Guegan J, Enot DP, et al. Cisplatin resistance associated with PARP hyperactivation. Cancer Res 2013; 73:2271-80; PMID:23554447; http://dx.doi.org/10.1158/0008-5472.CAN-12-3000.
99. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G. Molecular mechanisms of cisplatin resistance. Oncogene 2012; 31:1869-83; PMID:21892204; http://dx.doi. org/10.1038/onc.2011.384.
100. Galluzzi L, Senovilla L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology 2012; 1:1111-34; PMID:23170259; http://dx.doi.org/10.4161/onci.21494.
101. Vacchelli E, Vitale I, Eggermont A, Fridman WH, Fucíková J, Cremer I, Galon J, Tartour E, Zitvogel L, Kroemer G, et al. Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology 2013; 2:e25771; PMID:24286020; http://dx.doi. org/10.4161/onci.25771.
102. Vacchelli E, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunostimulatory cytokines. Oncoimmunology 2013; 2:e24850; PMID:24073369; http://dx.doi. org/10.4161/onci.24850.
103. Vacchelli E, Galluzzi L, Eggermont A, Galon J, Tartour E, Zitvogel L, Kroemer G. Trial Watch: Immunostimulatory cytokines. Oncoimmunology 2012; 1:493-506; PMID:22754768; http://dx.doi. org/10.4161/onci.20459.
104. Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012; 1:699-716; PMID:22934262; http://dx.doi. org/10.4161/onci.20696.
105. Vacchelli E, Galluzzi L, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial watch: FDAapproved Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012; 1:894-907; PMID:23162757; http://dx.doi.org/10.4161/onci.20931.
106. Vacchelli E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology 2013; 2:e25238; PMID:24083080; http://dx.doi.org/10.4161/onci.25238.
107. Tarhini AA. Tremelimumab: a review of development to date in solid tumors. Immunotherapy 2013; 5:215-29; PMID:23444951; http://dx.doi.org/10.2217/imt.13.9.
108. Bensinger W, Maziarz RT, Jagannath S, Spencer A, Durrant S, Becker PS, Ewald B, Bilic S, Rediske J, Baeck J, et al. A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. Br J Haematol 2012; 159:58-66; PMID:22861192; http://dx.doi. org/10.1111/j.1365-2141.2012.09251.x.
109. Alici E. IPH-2101, a fully human anti-NK-cell inhibitory receptor mAb for the potential treatment of hematological cancers. Curr Opin Mol Ther 2010; 12:724-33; PMID:21154164.
110. Chacon JA, Wu RC, Sukhumalchandra P, Molldrem JJ, Sarnaik A, Pilon-Thomas S, Weber J, Hwu P, Radvanyi L. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy. PLoS One 2013; 8:e60031; PMID:23560068; http://dx.doi.org/10.1371/journal. pone.0060031.
111. Vacchelli E, Vitale I, Tartour E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology 2013; 2:e25595; PMID:24319634; http://dx.doi.org/10.4161/onci.25595.
112. Brenner C, Galluzzi L, Kepp O, Kroemer G. Decoding cell death signals in liver inflammation. J Hepatol 2013; 59:583-94; PMID:23567086; http://dx.doi.org/10.1016/j.jhep.2013.03.033.
113. Rakoff-Nahoum S, Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer 2009; 9:57-63; PMID:19052556; http://dx.doi.org/10.1038/nrc2541.
114. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31:51-72; PMID:23157435; http://dx.doi.org/10.1146/annurev-immunol-032712-100008.
115. Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 2012; 12:860-75; PMID:23151605; http://dx.doi. org/10.1038/nrc3380.
116. Semeraro M, Vacchelli E, Eggermont A, Galon J, Zitvogel L, Kroemer G, et al. Trial Watch: Lenalidomide-based immunochemotherapy. OncoImmunology 2013; 2: e26494.
117. Stevanovic S. Identification of tumour-associated T-cell epitopes for vaccine development. Nat Rev Cancer 2002; 2:514-20; PMID:12094237; http://dx.doi.org/10.1038/nrc841.
118. Eggermont AM. Immunotherapy: Vaccine trials in melanoma-time for reflection. Nat Rev Clin Oncol 2009; 6:256-8; PMID:19390551; http://dx.doi. org/10.1038/nrclinonc.2009.42.
119. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449:419-26; PMID:17898760; http://dx.doi.org/10.1038/nature06175.
120. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12:265-77; PMID:22437871; http://dx.doi.org/10.1038/nrc3258.
121. Vacchelli E, Eggermont A, Fridman WH, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Adoptive cell transfer for anticancer immunotherapy. Oncoimmunology 2013; 2:e24238; PMID:23762803; http://dx.doi.org/10.4161/onci.24238.
122. Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial Watch: Adoptive cell transfer immunotherapy. Oncoimmunology 2012; 1:306-15; PMID:22737606; http://dx.doi.org/10.4161/onci.19549.
123. Hinrichs CS, Restifo NP. Reassessing target antigens for adoptive T-cell therapy. Nat Biotechnol 2013; 31:999-1008; PMID:24142051; http://dx.doi. org/10.1038/nbt.2725.
124. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012; 12:269-81; PMID:22437939; http://dx.doi.org/10.1038/nri3191.